3T Biosciences (3T), a US-based immunotherapy company, announced on Wednesday that it has named Bryan Irving, PhD as its new chief scientific officer (CSO).

In the new role, Dr Irving will be responsible for the company's scientific strategy and direction and will chair the company's Scientific Advisory Board.

Dr Irving has over 30 years of experience working across diverse disciplines of research and development (R&D) to deliver innovative medicines. During his career, he headed small-to-larger-scale organisations in drug discovery and development in multiple therapeutic areas, including immunology and oncology. His work is focussed on exploring ways to modulate T-cell activity for therapeutic benefit in both oncology and autoimmune settings.

He has served as senior advisor at Frazier Life Sciences, CSO at Amunix Pharmaceuticals, executive vice president and CSO of Five Prime Therapeutics, vice president and Cancer Immunology at CytomX. He started his career at Genentech, where for 12 years his work focused on biologics' drug discovery and development in both areas of inflammation and immune oncology.